

**QUARTERLY
INFORMATION**

STALLERGENES SALES REACH €45.7 MILLION IN Q3 2014
ORALAIR® ACHIEVES MARKET LEADERSHIP IN FRANCE
CONTINUED EXPANSION OF INTERNATIONAL MARKETS (UP 33%)

Antony, France; 23 October 2014 – 6.00pm CET

Total Q3 Net sales

€million	2013		2014		14/13
	€ m	%Sales	€ m	%Sales	Var. %
Southern Europe (1)	31,2	68	32,2	71	3,3
North & Central Europe	11,5	25	8,9	20	(22,2)
International Markets	3,2	7	4,3	9	33,0
USA	0,0	0	0,3	0	
Total Q3 Net Sales	45,9	100	45,7	100	(0,3)
Sublingual route	38,4	84	37,0	81	(3,6)
Subcutaneous route	5,6	12	6,0	13	7,6
Other products	1,9	4	2,8	6	42,5
Total Q3 Net Sales	45,9	100	45,7	100	(0,3)

Cumulative Net Sales (September 2014 in Year to Date)

€million	2013		2014		14/13
	€ m	%Sales	€ m	%Sales	Var. %
Southern Europe (1)	123,6	70	123,2	71	(0,3)
North & Central Europe	41,1	24	39,4	22	(4,0)
International Markets	9,9	6	12,5	7	25,8
USA	0,0	-	0,6	0	
Cumulative Net Sales	174,6	100	175,7	100	0,7
Sublingual route	149,9	86	149,4	85	(0,4)
Subcutaneous route	18,0	10	18,5	11	3,0
Other products	6,7	4	7,9	4	17,7
Cumulative Net Sales	174,6	100	175,7	100	0,7

(1) Portugal, Spain, France, Italy

Q3 2014 sales underpinned by Southern Europe and international markets

Consolidated sales for the third quarter of 2014 totalled €45.7 million, stable compared with the third quarter of 2013.

“Southern Europe” Region posted a strong performance with a growth of 3.3%, due to the performance of France where the new pump for the sublingual product Staloral[®] was successfully launched and where Oralair[®] has become the leader of the tablet market in a single year of launch.

“Northern and Central Europe” Region saw a slowdown due to Germany, which in 2013 had benefited from a positive effect related to a VAT refund. This slowdown was not offset by the strong performance of Switzerland (+20%) and Central European countries, such as Poland (+8%) and Hungary (+160%).

Outside Europe, international markets posted strong and sustained growth (up 33%), particularly in high potential markets such as Australia, Turkey and Russia. This performance confirms the relevance of the Group’s expansion strategy regarding new international markets, which, over the quarter, represented 9% of Group sales, versus 7% in Q3 2013.

Continued international expansion of the Group

In the sublingual segment, the five-grass pollen immunotherapy tablet Oralair[®] achieved the strongest sales growth on the tablet market, securing a global market share of 48%¹ in the grass pollen tablet segment. Available in 23 countries, Oralair[®] is continuing its expansion and will be launched in Turkey over the next few weeks.

In the US, Oralair[®], the first and only five-grass pollen sublingual immunotherapy tablet with a pre-co-seasonal protocol authorised in this country, has, since May 2014, been marketed by Greer Laboratories Inc., a US leader in allergen immunotherapy. With the first sales recorded during the pollen season due to the late launch of the product, prescriptions for the 2015 season will start in November 2014.

In addition, Stallergenes has strengthened its presence in North America with the creation of an affiliate in Canada, which will give the opportunity to reinforce initiatives previously undertaken by a local partner.

ABOUT STALLERGENES

STALLERGENES is a global healthcare company specialized in the diagnosis and treatment of allergies. For more than 50 years, it has been continuously expanding the existing frontiers of science in order to provide allergy patients with more effective long lasting therapeutic options. Thanks to its innovation strategy, fuelled by investments amounting to around 20% of total annual revenues as well as external partnerships, STALLERGENES is able to provide targeted allergen immunotherapy-based allergy solutions that significantly improve the lives of allergy patients around the world.

STALLERGENES operates in 21 countries and employs over 1,000 people. In 2013, the Company generated total revenues of €248 million, and more than 500,000 patients were treated with STALLERGENES products.

¹ IMS data: only for countries where Oralair[®] and Grazax[®] are both available. Sales over a rolling twelve-month period (July 2014).

Euronext Paris (Compartment B)
CAC small
ISIN: FR0000065674
Reuters: GEN.PA
Bloomberg: GEN.FP



Additional information is available at <http://www.stallergenes.com>

Forward-looking statements related to Stallergenes

This press release may contain forward-looking statements, including forecasts of future revenue and operating profit as well as expected business-related events. Such statements are based upon the current beliefs and expectations of Stallergenes' management and are subject to risks and uncertainties. Actual results may differ from those set forth in the forward-looking statements, due to various factors. Without being exhaustive, such factors include economic situations and business conditions, including legal and product evaluation issues, fluctuations in currencies and demand, changes in competitive factors and reliance on suppliers. The Company disclaims any intention or obligation to update or revise any forward-looking statements whether as a result of new information or future events and except as required by law.

Contacts:

Christian Chavy, Chief Executive Officer
Tel: +33 1 55 59 20 04

Investor and analyst relations

Peter Buhler
Chief Financial Officer
Tel: +33 1 55 59 20 95
Email: investorrelations@stallergenes.com

Media Relations

Lise Lemonnier
Senior Communication & Public Affairs Director
Tel: + 33 1 55 59 20 96
Email: llemonnier@stallergenes.com

Investor and press relations agency

FTI Consulting - Analyst and investor contact
Stephan Dubosq
Tel: +33 1 47 03 68 16
Email: stephan.dubosq@fticonsulting.com

FTI Consulting – Press contact
Jeanne Bariller
Tel: +33 1 47 03 68 63
Email: jeanne.bariller@fticonsulting.com